Mass Tort brief
Teva faces price-fixing pressure as class-action cost rules shift
A key competitor's cooperation squeezes Teva while Israeli courts target speculative litigation.
Mass Tort
A US generic price-fixing settlement with Glenmark has turned a key competitor into a state witness — a development that severely increases Teva’s multi-billion-dollar antitrust liability.
BackgroundTeva is the central defendant in the multi-state generic drug pricing antitrust multidistrict litigation. State attorneys general allege that a cartel of generic drugmakers conspired to artificially inflate prices and divide market shares.
- Glenmark's cooperation agreement provides prosecutors with internal communications and pricing logs, directly strengthening the states' case against the remaining major generic drugmakers.
- Teva, a heavyweight on the Tel Aviv Stock Exchange, faces potentially billions of dollars in joint-and-several liabilities if this multi-state antitrust case goes to trial.
- State attorneys general have secured $66.95 million in cumulative settlements from minor drugmakers, building a massive litigation fund to target the Tel Aviv-based pharmaceutical giant.
Mass Tort
A $10.2M US talc-asbestos verdict has assigned 15% liability to a Perrigo subsidiary — a legal shift proving private-label manufacturers face direct exposure in product liability waves.
BackgroundTalc litigation has primarily focused on major national brands like Johnson & Johnson. However, plaintiffs are increasingly targeting private-label producers who manufactured store-brand baby and body powders for major retailers like Walmart and Target.
- The jury found that the store-brand body powders were manufactured in a defective condition and lacked adequate safety warnings, exposing retailers to downstream liability.
- Perrigo Tennessee was assigned 15% of the total damages, establishing direct liability for the TASE-listed manufacturer in the ongoing US asbestos talc litigation.
- The verdict opens a new litigation front for store-brand producers, who previously believed they were insulated from major product liability payouts by manufacturing for others.
Mass Tort
The Supreme Court is introducing harsher cost orders for weak class actions — a pivotal policy reset that shields Israeli corporations from speculative litigation.
BackgroundIsrael has historically seen an exceptionally high volume of class-action filings due to a rule protecting plaintiffs from paying defendants' legal fees if a certification fails. Corporate defendants have long complained that this legal asymmetry encourages speculative and bad-faith lawsuits.
- The justices declined to completely abandon the protective moderation rule, seeking to avoid a chilling effect on legitimate, meritorious consumer claims in local courts.
- Concurring opinions emphasized that courts must place greater weight on the operational disruption and reputational harm imposed on corporate respondents during lengthy proceedings.
- The new guidelines will allow judges to penalize plaintiffs who prolong litigation without sufficient evidence, changing the risk calculation for Tel Aviv class action lawyers.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.